How to Help Your Patients Save Money on Prolia: A Provider's Guide to Savings Programs

At an average retail price of $2,296–$2,547 per single-use prefilled syringe, Prolia (denosumab) is one of the more expensive specialty medications providers administer. For uninsured patients, the annual cost exceeds $5,000. Even insured patients may face substantial copays, especially as biosimilar formulary switches complicate coverage in 2026. This guide equips your clinical team with every available cost-reduction resource.

Why Patient Cost Matters for Adherence — and Clinical Outcomes

Prolia is unique in that non-adherence carries a clinical penalty beyond simple treatment gaps. Stopping denosumab without transitioning to another antiresorptive agent triggers a rebound in bone resorption that dramatically increases fracture risk — including multiple vertebral fractures. When patients stop because they can't afford the next dose, this is a clinical emergency in slow motion. Proactively connecting patients with financial assistance is not just service — it's patient safety.

Option 1: Amgen SupportPlus Co-Pay Program (Commercially Insured Patients)

The Amgen SupportPlus Co-Pay Program is the most impactful savings tool for commercially insured patients. Eligible patients can have their out-of-pocket cost reduced to as little as $0 per dose. This covers the patient's copay, coinsurance, and deductible (up to annual maximums).

• Eligibility: Commercially insured patients with approved prescription; NOT available for Medicare, Medicaid, or VA beneficiaries
• Enrollment: 1-866-264-2778 or amgensupportplus.com; your practice coordinator can enroll on behalf of the patient
• Annual renewal: Enrollment should be renewed each calendar year — build this into your practice's annual workflow

Option 2: Amgen Patient Assistance Program (Uninsured/Underinsured Patients)

For patients without insurance who meet income eligibility criteria, Amgen's Patient Assistance Program can provide Prolia at no charge for up to one year. Your office can help initiate the application, which typically requires income documentation, a signed prescriber statement, and proof of no drug coverage.

Amgen SupportPlus case managers will ship the drug directly to your practice. Coordinate with your specialty drug ordering workflow to ensure timely delivery.

Option 3: Independent Foundations — PAN Foundation and Others

Independent nonprofit patient assistance programs fill the gap for Medicare and Medicaid patients who are ineligible for the manufacturer's commercial co-pay card. Key programs include:

• PAN Foundation: 1-866-316-7263 | panfoundation.org | Assistance for Medicare/Medicaid patients and underinsured; eligibility based on income and diagnosis
• HealthWell Foundation: healthwellfoundation.org | Copay assistance for patients with serious illness who meet income requirements
• NeedyMeds: needymeds.org | Comprehensive database of patient assistance programs by drug name

Option 4: Optimize Medicare Coverage

For Medicare patients, how and where Prolia is administered affects coverage and cost:

• Medicare Part B: Covers Prolia when administered in your office. Medicare pays 80%, and with Medigap supplemental coverage, the patient's share can be $0. This is often the lowest-cost pathway for your Part B patients.
• Medicare Part D: Covers Prolia under pharmacy benefit; 96% of Part D enrollees have access as of early 2026. As of 2026, Part D has a $2,100 annual out-of-pocket cap.
• Extra Help / LIS: Low-income Medicare patients may qualify for the Extra Help program, which significantly reduces Part D copays and premiums. Screen all uninsured Medicare patients for eligibility.

Option 5: Biosimilar Cost Optimization

Nine FDA-approved denosumab biosimilars are now available as of 2026. Biosimilars are therapeutically equivalent and are often priced lower or preferred by insurance plans. Key biosimilar cost strategies:

• Check each patient's formulary for preferred biosimilar tier placement — a preferred biosimilar often has a lower copay than brand Prolia
• Several biosimilar manufacturers offer their own co-pay assistance programs — ask your specialty distributor for current details
• Document medical necessity for specific biosimilars if a patient has had a prior adverse reaction or formulary exception is needed

Building a Cost-Support Workflow into Your Practice

For practices administering Prolia regularly, consider building these steps into your workflow:

1. At the time of Prolia initiation, screen for insurance type and enroll eligible patients in Amgen SupportPlus or refer to foundation programs.
2. Annually, confirm co-pay card enrollment renewal before the patient's first dose of the new calendar year.
3. Review formulary changes for biosimilar preferred status each fall during open enrollment season.
4. Flag uninsured patients for PAP application before the first injection — early enrollment prevents delays.

For providers who need help identifying where patients can source Prolia when supply issues arise, medfinder for providers offers a fast, staff-friendly way to locate nearby dispensing sites — reducing the burden on your team while keeping patients on schedule.

Also see: How to Help Your Patients Find Prolia in Stock: A Provider's Guide.